Clinical Study

Phase II Double-Blinded Placebo-Controlled Study Of Bevacizumab With Or Without Amg 386 In Patients With Recurrent Glioblastoma Or Gliosarcoma.

Posted Date: May 15, 2019

  • Investigator: Kevin Redmond
  • Specialties:
  • Type of Study: Drug

This study will find effects of Bevacizumab with or without AMG 386 on brain tumors. The FDA has approved bevacizumab for recurrent GBM. However, bevacizumab alone has only modestly improved overall survival. For this reason, other drugs, such as AMG 386, are being evaluated. AMG 386 is investigatio

Criteria:

Eligible Patients Must Have A Brain Tumor, Called A Glioblastoma Or Gliosarcoma, Which Has Become Wo

Keywords:

Brain Cancer, Brain Tumor, Gbm, Neuro-Oncology, R1122

For More Information:

Uc Cancer Institute
513-584-7698
kastla@ucmail.uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.